central nervous system disorder

In conjunction with its 51 percent stake in Immuneering, Teva will have the right of first refusal in projects related to CNS disorder treatments. 

NEW YORK (GenomeWeb News) – The Icahn School of Medicine at Mt. Sinai and biopharmaceutical firm Berg today announced a five-year partnership aimed at cancer, as well as central nervous system and endocrine disorders.

NEW YORK (GenomeWeb News) – Roche today announced that it has teamed with the Innovative Medicines Initiative to lead a consortium of industry and academic partners that will use stem cells for drug discovery research.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – UK-based NextGen Group announced this week it has completed the formation of a diagnostics subsidiary to develop tests for central nervous system disorders.

Using its DiscoveryMAP protein biomarker discovery platform, the company identified a biomarker pattern useful in monitoring disease progression and predicting and monitoring the efficacy of a compound in Roche's CNS pipeline.

The firms will offer clients access to their complementary drug discovery platforms for identifying and developing new therapeutics for CNS disorders.

The companies will co-develop seven assays for pathogens associated with respiratory, enteric, and central nervous system diseases.

The work identified 1,461 proteins tied to more than130 brain diseases, suggesting that synaptic proteins may figure more prominently in nervous system disorders than previously thought and could represent promising new targets for drug development.

Sage will develop a predictive model and identify regulatory genes and predictive biomarkers. The two partners will then discover and prioritize the targets.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.